Skip to content


REsearch summary

VIC seeks to accelerate the efficient & effective early-stage development of new vaccines & immunotherapies for infectious disease.

VIC has been successful in developing novel candidate vaccines and adjuvants for emerging infectious diseases and exploring intriguing aspects of their immunopathogenesis.

To this end current research priorities include:

Infectious Disease Pipeline

1 : Initial R&D

2 : Preclinical Efficacy

3 : Preclinical Safety

4 : Initial Human Studies

Highlighted Publications

Front Immunol. 2019 Feb 15;10:207. doi: 10.3389/fimmu.2019.00207. eCollection 2019. PMID: 30828331
Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC.

FASEB J. 2019 Feb;33(2):3074-3081. doi: 10.1096/fj.201801095R. Epub 2018 Sep 7. PMID:30192655
Gelfand JA, Nazarian RM, Kashiwagi S, Brauns T, Martin B, Kimizuka Y, Korek S, Botvinick E, Elkins K, Thomas L, Locascio J, Parry B, Kelly KM, Poznansky MC.

explore these labs for more info